These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 24949999)
1. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement. Rappaport J; Garnacho C; Muro S Mol Pharm; 2014 Aug; 11(8):2887-95. PubMed ID: 24949999 [TBL] [Abstract][Full Text] [Related]
3. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793 [TBL] [Abstract][Full Text] [Related]
4. Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery. Rappaport J; Manthe RL; Garnacho C; Muro S Mol Pharm; 2015 May; 12(5):1366-76. PubMed ID: 25849869 [TBL] [Abstract][Full Text] [Related]
5. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice. Garnacho C; Dhami R; Solomon M; Schuchman EH; Muro S Mol Ther; 2017 Jul; 25(7):1686-1696. PubMed ID: 28606376 [TBL] [Abstract][Full Text] [Related]
6. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581 [TBL] [Abstract][Full Text] [Related]
7. Manthe RL; Rappaport JA; Long Y; Solomon M; Veluvolu V; Hildreth M; Gugutkov D; Marugan J; Zheng W; Muro S J Pharmacol Exp Ther; 2019 Sep; 370(3):823-833. PubMed ID: 31101681 [TBL] [Abstract][Full Text] [Related]
8. Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting. Ansar M; Serrano D; Papademetriou I; Bhowmick TK; Muro S ACS Nano; 2013 Dec; 7(12):10597-611. PubMed ID: 24237309 [TBL] [Abstract][Full Text] [Related]
9. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement. Garnacho C; Muro S J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212 [TBL] [Abstract][Full Text] [Related]
10. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213 [TBL] [Abstract][Full Text] [Related]
11. Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrier. Loeck M; Placci M; Muro S Drug Deliv Transl Res; 2023 Dec; 13(12):3077-3093. PubMed ID: 37341882 [TBL] [Abstract][Full Text] [Related]
12. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Hsu J; Northrup L; Bhowmick T; Muro S Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578 [TBL] [Abstract][Full Text] [Related]
13. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes. Papademetriou I; Tsinas Z; Hsu J; Muro S J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603 [TBL] [Abstract][Full Text] [Related]
14. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers. Hsu J; Hoenicka J; Muro S Pharm Res; 2015 Apr; 32(4):1264-78. PubMed ID: 25319100 [TBL] [Abstract][Full Text] [Related]
15. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Muro S; Garnacho C; Champion JA; Leferovich J; Gajewski C; Schuchman EH; Mitragotri S; Muzykantov VR Mol Ther; 2008 Aug; 16(8):1450-8. PubMed ID: 18560419 [TBL] [Abstract][Full Text] [Related]
16. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Papademetriou IT; Garnacho C; Schuchman EH; Muro S Biomaterials; 2013 Apr; 34(13):3459-66. PubMed ID: 23398883 [TBL] [Abstract][Full Text] [Related]
18. Uptake and degradation of several pyrenesphingomyelins by skin fibroblasts from control subjects and patients with Niemann-Pick disease. Effect of the structure of the fluorescent fatty acyl residue. Levade T; Gatt S; Salvayre R Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):211-7. PubMed ID: 2018477 [TBL] [Abstract][Full Text] [Related]